secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093307
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron Q2 net loss $67.4M; RYTELO launch underway with ~160 patients treated by July 31
--------------------------------------------------------------------------------

- Net loss of $67.4M ($0.10 per share) for Q2 2024, compared to $49.2M ($0.09) in Q2 2023.
- RYTELO (imetelstat) commercially launched June 27, 2024; estimated ~160 patients treated as of July 31, 2024.
- Total product revenue $780k for Q2; net revenue $882k (vs $29k prior year period).
- Cash and marketable securities $430.4M as of June 30, 2024; FY2024 operating expenses guided to $270M-$280M.
- NCCN Guidelines updated to include RYTELO as Category 1 for second-line and Category 2A for first-line LR-MDS treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017024093307/0000950170-24-093307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017024093307/gern-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer